Biocardia announces completion of enrollment in phase iii cardiamp hf trial and plans for cardiamp hf trial ii

Sunnyvale, calif., oct. 11, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces completion of enrollment in its cardiamp heart failure trial and initiation of a discussion with the fda on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining fda marketing approval.
BCDA Ratings Summary
BCDA Quant Ranking